Innovative Financing for Novel Therapies Isha Bangia PhamD MBA Ulrich Neumann FRSA, MBA, MSC MA We would like to acknowledge the research of Maximilian Vargas, PhD MBA. Email: eva-bd@certara.com The Advent of Transformative Medicines as a Driver for Payment Innovation • The advent of transformative and gene therapies has amplified affordability concerns among payers, providers and patients. Stakeholders agree that both funding and delivery systems are inadequate to deal with a wave of future cures. Until recently, little had changed in the thinking about how to pay for and deliver these therapeutic innovations. • With respect to gene therapies, different US payer types are variably exposed to three core risks: • Actuarial uncertainty (how many eligible patient

Join for free to read